


Supplemental Data

Sample Lot and Vial Number	Calculated PSMA-617 Mass (µg/mL)			
	Gradient		Isocratic	
Method Used				
UV Wavelength Analyzed	277	225	277	225
LPS240416B-25 Vial# 29	5.95	5.92	5.89	7.57
LPS240423A-25 Vial# 10	6.20	6.75	5.28	5.61
LPS240423A-25 Vial# 11	6.53	6.66	6.60	5.02
LPS240528B-25 Vial# 2	6.73	7.23	7.58	6.91
LPS240611A-25 Vial# 26	6.61	6.57	5.38	5.30
LPS240716B-25 Vial# 18	6.25	6.19	5.70	7.51
LPS240730B-25 Vial# 24	6.16	6.22	5.31	7.53
LPS240806B-25 Vial# 25	5.95	5.88	5.72	7.13
Average	5.93	6.57	6.30	6.43
Standard Deviation	0.79	1.08	0.30	0.46

Supplemental Table 1: Calculated PSMA-617 mass for the 8 Pluvicto samples using each of the four standard curves

Supplemental Figure 1: radioHPLC Analysis of 8 clinical Pluvicto Doses



Supplemental Figure 1: Standard curves using 5 PSMA-617 concentrations (0.5, 1, 5, 10, and 50 $\mu\text{g/mL}$) with a gradient method at UV 225 (A_{max} , maximum absorbance) and 277 (λ_{max} , maximum absorbance for PSMA-617) (**a**) and isocratic method at UV 225 and 277 (**b**), Calculated PSMA-617 mass using 8 clinical Pluvicto doses (**c**), and representative radioHPLC chromatogram demonstrating overlay between PSMA-617 UV trace at 225 nm (retention time 2.892 min) and radioactive trace (retention time 2.975 min; offset due to line volume between detectors) (**d**).